List of Veeva AI Customers
Pleasanton, 94588, CA,
United States
Since 2010, our global team of researchers has been studying Veeva AI customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Veeva AI for Chatbots and Conversational AI from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Veeva AI for Chatbots and Conversational AI include: Roche, a Switzerland based Life Sciences organisation with 112774 employees and revenues of $80.28 billion, Bayer, a Germany based Life Sciences organisation with 92815 employees and revenues of $55.47 billion, Novo Nordisk, a Denmark based Life Sciences organisation with 78554 employees and revenues of $45.92 billion, Moderna, a United States based Life Sciences organisation with 5600 employees and revenues of $6.75 billion and many others.
Contact us if you need a completed and verified list of companies using Veeva AI, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Veeva AI customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Bayer | Life Sciences | 92815 | $55.5B | Germany | Veeva Systems | Veeva AI | Chatbots and Conversational AI | 2023 | n/a |
In 2023 Bayer committed to move to Veeva Vault CRM globally to harmonize customer master data and to be positioned to leverage AI driven engagement across channels and geographies. The Vault CRM commitment is a global commercial and CRM initiative and positions Bayer to adopt Veeva AI within the Chatbots and Conversational AI category for conversational access to CRM data and customer engagement workflows.
Implementation emphasis centers on consolidating customer master data and standardizing account and contact records inside Veeva Vault CRM, while enabling conversational agent workflows. Veeva AI is expected to support Vault CRM Bot and Voice Agent style interactions, delivering contextual CRM lookups, guided representative workflows, and conversational retrieval of approved content, consistent with Chatbots and Conversational AI functional patterns.
Operational coverage is described as global commercial operations, aligning sales, medical affairs, and customer engagement teams under a unified customer master data model and Vault CRM instance. Integrations are focused on synchronizing customer master data and channel touchpoints to provide contextual inputs for conversational agents and to maintain CRM audit trails required for life sciences commercial functions.
Governance and rollout planning emphasize customer master data stewardship, conversational agent oversight, and staged regional enablement to ensure consistent messaging and compliance across markets. The stated objective of the program is to harmonize customer master data and position Bayer to leverage Veeva AI driven engagement across channels and geographies.
|
 |
Moderna | Life Sciences | 5600 | $6.8B | United States | Veeva Systems | Veeva AI | Chatbots and Conversational AI | 2025 | n/a |
In 2025 Moderna implemented Veeva AI in the Chatbots and Conversational AI category to accelerate MLR reviews for commercial and medical content workflows. The deployment centers on Veeva AI for Vault PromoMats using the Quick Check Agent to provide automated review assistance directly within PromoMats.
The implementation leverages the Veeva AI Quick Check Agent capability to surface compliance guidance, flag medical and regulatory risk language, and generate contextual review suggestions to support MLR decisioning. These conversational AI capabilities are applied to content ingestion, automated checklist validation, and reviewer query handling to reduce manual triage in promotional content pipelines.
Integrations were focused on Vault PromoMats, embedding Veeva AI into existing content authoring and approval paths across commercial and medical content processes, and the use case was presented alongside Europe and global examples at the Veeva Commercial Summit. Veeva described the Moderna deployment as an early access first-customer scenario, and the rollout included governance adjustments to incorporate AI-assisted checkpoints into MLR workflows, with Veeva noting the approach speeds MLR content reviews to shorten approval cycle times.
|
 |
Novo Nordisk | Life Sciences | 78554 | $45.9B | Denmark | Veeva Systems | Veeva AI | Chatbots and Conversational AI | 2026 | n/a |
In 2026, Novo Nordisk implemented Veeva AI from Veeva Systems within its International Operations business unit, deploying the agentic capabilities as part of the Vault CRM Suite to advance customer engagement. The implementation is positioned under the Chatbots and Conversational AI category and is intended to support next generation commercial execution across personal and digital channels.
The deployment emphasizes agentic AI and deep application workflows native to Veeva Vault CRM, including conversational automation for field teams, digital engagement orchestration, and contextual CRM record augmentation. Veeva AI and the Vault CRM Suite are described as providing advanced global capabilities to address country specific business and compliance requirements, indicating configuration for multi-jurisdictional regulatory logic and controlled content delivery.
Operational coverage centers on Novo Nordisk International Operations with a clear focus on commercial functions, including sales execution, customer engagement, and digital channel management. The implementation narrative highlights orchestration between in-person field activity and digital touchpoints, and uses conversational AI patterns common in Chatbots and Conversational AI deployments to streamline customer interaction workflows and CRM data capture.
Governance is framed as an expansion of the strategic partnership between Novo Nordisk and Veeva Systems, with organization level commitment to Vault CRM as the technology foundation for commercial execution. Public statements by Novo Nordisk leadership and Veeva leadership position the Veeva AI adoption as intended to help deliver breakthrough medicines and to improve commercial execution, reflecting expected business alignment rather than quantified outcomes.
|
 |
|
Life Sciences | 112774 | $80.3B | Switzerland | Veeva Systems | Veeva AI | Chatbots and Conversational AI | 2025 | n/a |
|
Buyer Intent: Companies Evaluating Veeva AI
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||